title: Intermittent preventive therapy for malaria: arguments in favour of artesunate and sulphamethoxypyrazine - pyrimethamine combination.
abstract: Recent publications put a serious warning regarding the inefficacy of sulphadoxine-pyrimethamine (SP) for the intermittent preventive treatment of malaria in young children (IPTi). Recommendations for other therapies are being made. By using a different and better sulphonamide (sulphamethoxypyrazine), it is possible to manufacture fixed dose combination pills with artesunate and pyrimethamine. This combination permits a full therapy over 24 hours (dosing interval being 12 hours). It is recommended that this combination should be tested in future field studies of IPTi.
authors: ACT-ion Afrique, Brussels, Belgium. fhjansen@actionafrique.com
authors: Frans Herwig
authors: FH
authors: Jansen
mesh_terms: D000962:Antimalarials / Q000008:administration & dosage* / Q000627:therapeutic use; D037621:Artemisinins / Q000008:administration & dosage* / Q000627:therapeutic use; D000077332:Artesunate; D002648:Child; D004338:Drug Combinations; D018432:Drug Resistance, Multiple; D005260:Female; D006801:Humans; D007223:Infant; D008288:Malaria / Q000188:drug therapy* / Q000517:prevention & control*; D010961:Plasmodium / Q000187:drug effects; D011739:Pyrimethamine / Q000008:administration & dosage* / Q000627:therapeutic use; D013415:Sulfalene / Q000008:administration & dosage* / Q000627:therapeutic use
chemical_list: D000962:Antimalarials; D037621:Artemisinins; D004338:Drug Combinations; D000077332:Artesunate; D013415:Sulfalene; D011739:Pyrimethamine